Details of responses, according to EUMNET definitions, in patients included in Phase 2
| Response in . | Intention to treat (n = 30)* . | Per-protocol (n = 25) . |
|---|---|---|
| Anemia | ||
| CR | 0 (0.0) | 0 (0.0) |
| PR | 5 (25.0) | 4 (23.5) |
| Pro | 0 (0.0) | 0 (0.0) |
| NR | 15 (75.0) | 13 (76.5) |
| Leukocyte count | ||
| CR | 3 (15.0) | 2 (11.8) |
| PR | 0 (0.0) | 0 (0.0) |
| NR | 17 (85.0) | 15 (88.2) |
| Platelet count | ||
| CR | 5 (25.0) | 4 (25.0) |
| PR | 0 (0.0) | 0 (0.0) |
| NR | 15 (75.0) | 12 (75.0) |
| Splenomegaly | ||
| CR | 2 (6.7) | 2 (8.0) |
| PR | 11 (36.7) | 10 (40.0) |
| Pro | 1 (3.1) | 0 (0.0) |
| NR | 16 (53.3) | 13 (52.0) |
| Constitutional symptoms | ||
| CR | 11 (68.7) | 11 (78.6) |
| Pro | 1 (6.2) | 1 (7.2) |
| NR | 4 (25.0) | 2 (14.3) |
| Pruritus | ||
| CR | 16 (80.0) | 14 (87.5) |
| NR | 4 (20.0) | 2 (12.5) |
| Response in . | Intention to treat (n = 30)* . | Per-protocol (n = 25) . |
|---|---|---|
| Anemia | ||
| CR | 0 (0.0) | 0 (0.0) |
| PR | 5 (25.0) | 4 (23.5) |
| Pro | 0 (0.0) | 0 (0.0) |
| NR | 15 (75.0) | 13 (76.5) |
| Leukocyte count | ||
| CR | 3 (15.0) | 2 (11.8) |
| PR | 0 (0.0) | 0 (0.0) |
| NR | 17 (85.0) | 15 (88.2) |
| Platelet count | ||
| CR | 5 (25.0) | 4 (25.0) |
| PR | 0 (0.0) | 0 (0.0) |
| NR | 15 (75.0) | 12 (75.0) |
| Splenomegaly | ||
| CR | 2 (6.7) | 2 (8.0) |
| PR | 11 (36.7) | 10 (40.0) |
| Pro | 1 (3.1) | 0 (0.0) |
| NR | 16 (53.3) | 13 (52.0) |
| Constitutional symptoms | ||
| CR | 11 (68.7) | 11 (78.6) |
| Pro | 1 (6.2) | 1 (7.2) |
| NR | 4 (25.0) | 2 (14.3) |
| Pruritus | ||
| CR | 16 (80.0) | 14 (87.5) |
| NR | 4 (20.0) | 2 (12.5) |
Response in pruritus was declared only in subjects who reported CR of the symptom, such as for constitutional symptoms.
CR indicates complete response; EUMNET, European Network for Myelofibrosis;PR, partial response; Pro, progression; and NR, no response.
The number of patients evaluable for each of the end points differs depending on their baseline characteristics.